Journal article
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials
Cancer, Vol.125(1), pp.18-44
01/01/2019
DOI: 10.1002/cncr.31719
PMCID: PMC6860362
PMID: 30281145
Abstract
Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.
Details
- Title: Subtitle
- Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials
- Creators
- Joanne M Jeter - Department of Medicine, Divisions of Genetics and Oncology, The Ohio State University, Columbus, OhioTawnya L Bowles - Department of Surgery, Intermountain Health Care, Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UtahClara Curiel-Lewandrowski - Department of Medicine, The University of Arizona Cancer Center, Tucson, ArizonaSusan M Swetter - Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University Medical Center Cancer Institute, Veterans Affairs Palo Alto Health Care System, Palo Alto, CaliforniaFabian V Filipp - Systems Biology and Cancer Metabolism, Program for Quantitative Systems Biology, University of California Merced, Merced, CaliforniaZalfa A Abdel-Malek - Department of Dermatology, University of Cincinnati, Cincinnati, OhioLarisa J Geskin - Department of Dermatology, Cutaneous Oncology Center, Columbia University Medical Center, New York, New YorkJerry D Brewer - Department of Dermatologic Surgery, Mayo Clinic Minnesota, Rochester, MinnesotaJack L Arbiser - Division of Dermatology, Veterans Affairs Medical Center, Atlanta, GeorgiaJeffrey E Gershenwald - Departments of Surgical Oncology and Cancer Biology, Melanoma and Skin Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TexasEmily Y Chu - Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaJohn M Kirkwood - Melanoma and Skin Cancer Program, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PennsylvaniaNeil F Box - Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, ColoradoPauline Funchain - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OhioDavid E Fisher - Department of Dermatology, Massachusetts General Hospital, Boston, MassachusettsKari L Kendra - Department of Internal Medicine, Medical Oncology Division, The Ohio State University, Columbus, OhioAshfaq A Marghoob - Memorial Sloan Kettering Skin Cancer Center and Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New YorkSuephy C Chen - Division of Dermatology, Veterans Affairs Medical Center, Atlanta, GeorgiaMichael E Ming - Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaMark R Albertini - Department of Medicine, University of Wisconsin, School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, William S. Middleton Memorial Veterans Hospital, Madison, WisconsinJohn T Vetto - Division of Surgical Oncology, Oregon Health & Science University, Portland, OregonKim A Margolin - Department of Medical Oncology, City of Hope National Medical Center, Duarte, CaliforniaSherry L Pagoto - Department of Allied Health Sciences, UConn Institute for Collaboration in Health, Interventions, and Policy, University of Connecticut, Storrs, ConnecticutJennifer L Hay - Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New YorkDouglas Grossman - Departments of Dermatology and Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UtahDarrel L Ellis - Department of Medicine, Tennessee Valley Healthcare System, Nashville Veterans Affairs Medical Center, Nashville, TennesseeMohammed Kashani-Sabet - Center for Melanoma Research and Treatment, California Pacific Medical Center, San Francisco, CaliforniaAaron R Mangold - Department of Dermatology, Mayo Clinic, Scottsdale, ArizonaSvetomir N Markovic - Department of Hematology and Oncology, Mayo Clinic, Rochester, MinnesotaFrank L Meyskens JrKelly C Nelson - Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TexasJennifer G Powers - Department of Dermatology, University of Iowa, Iowa City, IowaJune K Robinson - Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IllinoisDebjani Sahni - Department of Dermatology, Boston Medical Center, Boston, MassachusettsAleksandar Sekulic - Department of Dermatology, Mayo Clinic, Scottsdale, ArizonaVernon K Sondak - Departments of Oncologic Sciences and Surgery, University of South Florida Morsani College of Medicine, Tampa, FloridaMaria L Wei - Dermatology Service, San Francisco Veterans Affairs Medical Center, San Francisco, CaliforniaJonathan S Zager - Department of Sarcoma, H. Lee Moffitt Cancer Center, Tampa, FloridaRobert P Dellavalle - Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, ColoradoJohn A Thompson - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WashingtonMartin A Weinstock - Department of Dermatology, Rhode Island Hospital, Providence, Rhode IslandSancy A Leachman - Department of Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, OregonPamela B Cassidy - Department of Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.125(1), pp.18-44
- DOI
- 10.1002/cncr.31719
- PMID
- 30281145
- PMCID
- PMC6860362
- NLM abbreviation
- Cancer
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Publisher
- United States
- Grant note
- R00 CA154887 / NCI NIH HHS K99 CA154887 / NCI NIH HHS P30 CA086862 / NCI NIH HHS
- Language
- English
- Date published
- 01/01/2019
- Academic Unit
- Dermatology
- Record Identifier
- 9984025476002771
Metrics
20 Record Views